NCT05765279

A Study to Assess the Efficacy of HH-120 Nasal Spray for Prevention of SARS-CoV-2 Infection in Adult Close Contacts of Individuals Infected With SARS-CoV-2

An Investigator Initiated Clinical Study To Evaluate the Efficacy and Safety of HH-120 Nasal Spray as Post Exposure Prophylaxis (PEP) Regimen in Adult Close Contacts of Individuals Infected With SARS-CoV-2

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 281 (actual)
• Sponsor: Beijing Ditan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

An Investigator-initiated, Randomized, Single-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of SARS-Cov-2 Post Exposure Prophylaxis and Safety of HH-120 nasal spray

Conditions

• SARS-CoV-2 Infection

Interventions

Type	Name	Description
DRUG	HH-120 nasal spray 1	HH-120 nasal spray 5 times daily for 3 consecutive days
DRUG	HH-120 nasal spray 2	HH-120 nasal spray 8 times daily for 3 consecutive days
DRUG	Placebo Comparator 1	Placebo nasal spray 5 times daily for 3 consecutive days
DRUG	Placebo Comparator 2	Placebo nasal spray 8 times daily for 3 consecutive days

Timeline

• Start date: 2022-10-20
• Primary completion: 2022-12-06
• Completion: 2022-12-06
• First posted: 2023-03-13
• Last updated: 2023-03-13

Locations

1 site across 1 country: China